Axsome Therapeutics, Inc.· AXSM

🇺🇸 US · LargeBroad USNASDAQ

Healthcare Biotechnology Website

Price: $206.68
Day: -0.80%
Mkt Cap: $10.64B
52W Range: $112.90 – $260.19
Volume: 438.2K
Beta: 0.60

5D Framework

Company Overview

Snapshot of fundamentals, performance, and 5D scores.

Blog

Company Profile

Business fundamentals and company information

Business Description

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Key Details

CEO

Herriot Tabuteau

Employees

1,346

Headquarters

New York City, NY, US

IPO Date

Nov 2015

Exchange

NASDAQ Global Market

Phone

212 332 3241

Healthcare · Biotechnology

SEC filings

10-KFeb 23, 2026 10-QAug 10, 2026 8-KAug 10, 2026

Price Performance

Recent price action and historical returns

Price Performance

$206.68

Historical Returns

Price performance over time

1 Day

-0.80%

5 Day

+3.85%

1 Month

-2.90%

3 Months

-11.04%

6 Months

+27.32%

YTD

+13.16%

1 Year

+66.13%

3 Years

+162.38%

5 Years

+674.37%

10 Years

+2742.92%

Revenue Analysis

How the business makes money, by product and geography

2025 revenue · 1 products

Revenue to Profit Flow · 2025

How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A). Operating costs ran past gross profit this year, so the shortfall enters as its own band and the rest of the P&L is listed under the chart.

Learn how to read flow diagrams

Below the line. Nothing flows through an operating loss, so these are shown as figures rather than as flows.

Operating Loss-$169.24M
Other expenses-$7.91M
Interest-$6.56M
Tax$530.00K
Net Loss-$183.17M

5D Framework

Five lenses on the stock. Click any card to dive deeper.

Quality

Business fundamentals

1.7/5

Weak

View Details

Peers

Competitive position

1.8/5

Weak

View Details

Valuation

Model-based valuation (vs. price)

1.0/5

Well above estimate

View Details

Analysts

Wall Street sentiment

4.1/5

Bullish

View Details

Holdings

Smart money flows

4.0/5

Bullish

View Details

How to read these dimensions

The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.